Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qishen granule is a Traditional Chinese Medicine (TCM) herbal formulation developed by the First Affiliated Hospital of Guangzhou University of Chinese Medicine. It is primarily indicated for the treatment of dilated cardiomyopathy (DCM) and chronic heart failure. The formulation is designed based on the TCM therapeutic strategy of invigorating Qi and activating blood (益气活血), typically containing herbs such as *Astragalus membranaceus* (Huangqi) and *Salvia miltiorrhiza* (Danshen). Clinical research, including trial ChiCTR2300072903, investigates its efficacy in improving cardiac function, reducing myocardial fibrosis, and addressing the innovative pathogenesis of heart failure in DCM patients. It is often used as an optimized prescription in clinical trials to evaluate its efficacy against standard care in cardiovascular disease management.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qishen granule.